<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Siegler JE</submitter><funding>NINR NIH HHS</funding><funding>NINDS NIH HHS</funding><pubmed_abstract>BackgroundEndovascular therapy (EVT) for stroke due to distal or medium vessel occlusion (DMVO) is safe. Due to the distinct anatomical characteristics of DMVOs, further evaluation of EVT is crucial to determine which devices may yield better outcomes.MethodsA retrospective analysis of adults with DMVO treated in 37 centers (11 countries) was queried. The primary outcome of favorable shift in 90-day modified Rankin Scale (mRS) was compared between patients treated with Trevo versus other devices on first pass using 1:1 propensity score matching (PSM) with multivariable adjustment. Secondary outcomes included the number of pass attempts, final thrombolysis in cerebral infarction (TICI) score 2b-3, symptomatic intracranial hemorrhage (sICH), improvement in National Institutes of Health Strok</pubmed_abstract><journal>Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences</journal><pagination>15910199251341603</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12095220</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A multicenter, propensity score-matched analysis of functional outcomes and recanalization success with or without Trevo for Medium and distal vessel occlusion.</pubmed_title><pmcid>PMC12095220</pmcid><funding_grant_id>R61 NS135583</funding_grant_id><funding_grant_id>R25 NS065743</funding_grant_id><funding_grant_id>UE5 NS065743</funding_grant_id><funding_grant_id>U24 NS113844</funding_grant_id><funding_grant_id>R21 NR020231</funding_grant_id><funding_grant_id>R21 NS131756</funding_grant_id><pubmed_authors>Pedicelli A</pubmed_authors><pubmed_authors>Griessenauer CJ</pubmed_authors><pubmed_authors>Harker P</pubmed_authors><pubmed_authors>Costalat V</pubmed_authors><pubmed_authors>Filipe JP</pubmed_authors><pubmed_authors>Mohlenbruch MA</pubmed_authors><pubmed_authors>Scarcia L</pubmed_authors><pubmed_authors>Daraghma M</pubmed_authors><pubmed_authors>Varela R</pubmed_authors><pubmed_authors>Baker A</pubmed_authors><pubmed_authors>Regenhardt RW</pubmed_authors><pubmed_authors>Barreau X</pubmed_authors><pubmed_authors>Rana A</pubmed_authors><pubmed_authors>Liebeskind DS</pubmed_authors><pubmed_authors>Yedavalli V</pubmed_authors><pubmed_authors>Essibayi MA</pubmed_authors><pubmed_authors>Sheth SA</pubmed_authors><pubmed_authors>MAD MT Investigators</pubmed_authors><pubmed_authors>Vigilante N</pubmed_authors><pubmed_authors>Mowla A</pubmed_authors><pubmed_authors>Spears J</pubmed_authors><pubmed_authors>Puri AS</pubmed_authors><pubmed_authors>Faizy TD</pubmed_authors><pubmed_authors>Pereira VM</pubmed_authors><pubmed_authors>Shaikh H</pubmed_authors><pubmed_authors>Khalife J</pubmed_authors><pubmed_authors>Biswas A</pubmed_authors><pubmed_authors>Koneru M</pubmed_authors><pubmed_authors>Henninger N</pubmed_authors><pubmed_authors>Altschul D</pubmed_authors><pubmed_authors>Tan BY</pubmed_authors><pubmed_authors>Stracke CP</pubmed_authors><pubmed_authors>Guenego A</pubmed_authors><pubmed_authors>Gonzalez NR</pubmed_authors><pubmed_authors>Tancredi I</pubmed_authors><pubmed_authors>Kuhn AL</pubmed_authors><pubmed_authors>Ota T</pubmed_authors><pubmed_authors>Kalsoum E</pubmed_authors><pubmed_authors>Dyzmann C</pubmed_authors><pubmed_authors>Bernstock JD</pubmed_authors><pubmed_authors>Gory B</pubmed_authors><pubmed_authors>Dmytriw AA</pubmed_authors><pubmed_authors>Lubicz B</pubmed_authors><pubmed_authors>Colasurdo M</pubmed_authors><pubmed_authors>Abdalkader M</pubmed_authors><pubmed_authors>Heit JJ</pubmed_authors><pubmed_authors>Jabbour P</pubmed_authors><pubmed_authors>Siegler JE</pubmed_authors><pubmed_authors>Radu RA</pubmed_authors><pubmed_authors>Adeeb N</pubmed_authors><pubmed_authors>Cancelliere NM</pubmed_authors><pubmed_authors>Clarencon F</pubmed_authors><pubmed_authors>Patel AB</pubmed_authors><pubmed_authors>Renieri L</pubmed_authors><pubmed_authors>Nguyen TN</pubmed_authors><pubmed_authors>Klein P</pubmed_authors><pubmed_authors>Ghozy S</pubmed_authors><pubmed_authors>Musmar B</pubmed_authors><pubmed_authors>Sundararajan SH</pubmed_authors><pubmed_authors>Marotta TR</pubmed_authors><pubmed_authors>Kass-Hout T</pubmed_authors><pubmed_authors>Naamani KE</pubmed_authors><pubmed_authors>Salim HA</pubmed_authors><pubmed_authors>Hecker C</pubmed_authors><pubmed_authors>Morsi RZ</pubmed_authors><pubmed_authors>Fiehler J</pubmed_authors><pubmed_authors>Alexandre AM</pubmed_authors><pubmed_authors>Rouchaud A</pubmed_authors></additional><is_claimable>false</is_claimable><name>A multicenter, propensity score-matched analysis of functional outcomes and recanalization success with or without Trevo for Medium and distal vessel occlusion.</name><description>BackgroundEndovascular therapy (EVT) for stroke due to distal or medium vessel occlusion (DMVO) is safe. Due to the distinct anatomical characteristics of DMVOs, further evaluation of EVT is crucial to determine which devices may yield better outcomes.MethodsA retrospective analysis of adults with DMVO treated in 37 centers (11 countries) was queried. The primary outcome of favorable shift in 90-day modified Rankin Scale (mRS) was compared between patients treated with Trevo versus other devices on first pass using 1:1 propensity score matching (PSM) with multivariable adjustment. Secondary outcomes included the number of pass attempts, final thrombolysis in cerebral infarction (TICI) score 2b-3, symptomatic intracranial hemorrhage (sICH), improvement in National Institutes of Health Strok</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 May</publication><modification>2026-06-02T20:59:16.898Z</modification><creation>2026-04-20T03:14:30.183Z</creation></dates><accession>S-EPMC12095220</accession><cross_references><pubmed>40398470</pubmed><doi>10.1177/15910199251341603</doi></cross_references></HashMap>